A Artrite Idiopática Juvenil (AIJ) é o nome dado a um grupo de doenças inflamatórias que afetam as articulações, de causa desconhecida, que começam antes dos 16 anos de idade e duram mais de 6 semanas. O termo artrite idiopática juvenil foi escolhido para indicar que não há um mecanismo conhecido que cause a doença e para ressaltar a necessidade de excluir outros tipos de artrite que surgem em condições médicas específicas (em particular, a artrite associada a doenças infecciosas, inflamatórias e hemato-oncológicas).
Introdução
O que você precisa saber de cara
Artrite idiopática juvenil refere-se a um grupo de condições que envolvem inflamação das articulações (artrite) que aparece pela primeira vez antes dos 16 anos de idade. Essa condição é um distúrbio autoimune, o que significa que o sistema imunológico funciona de forma inadequada e ataca os órgãos e tecidos do corpo, neste caso as articulações.
Pesquisadores descreveram sete tipos de artrite idiopática juvenil. Os tipos são diferenciados pelos seus sinais e sintomas, pelo número de articulações afetadas, pelos resultados de exames laboratoriais e pelo histórico familiar.
A artrite idiopática juvenil sistêmica causa inflamação em uma ou mais articulações. Uma febre alta diária que dura pelo menos 2 semanas precede ou acompanha a artrite. Pessoas com artrite sistêmica também podem apresentar erupção cutânea ou aumento dos linfonodos (linfadenopatia), do fígado (hepatomegalia) ou do baço (esplenomegalia).
A artrite idiopática juvenil oligoarticular (também conhecida como oligoartrite) é caracterizada pela ocorrência de artrite em quatro ou menos articulações nos primeiros 6 meses da doença. Ela é dividida em dois subtipos dependendo do curso da doença. Se a artrite permanecer confinada a quatro ou menos articulações após 6 meses, a condição é classificada como oligoartrite persistente. Se mais de quatro articulações forem afetadas após 6 meses, essa condição é classificada como oligoartrite estendida. Pessoas com oligoartrite têm risco aumentado de desenvolver inflamação do olho (uveíte).
A artrite idiopática juvenil poliarticular com fator reumatoide positivo (também conhecida como poliartrite, fator reumatoide positivo) causa inflamação em cinco ou mais articulações dentro dos primeiros 6 meses da doença. Pessoas com essa condição também apresentam um teste sanguíneo positivo para proteínas chamadas fatores reumatoides. Esse tipo de artrite se assemelha muito à artrite reumatoide observada em adultos.
A artrite idiopática juvenil poliarticular com fator reumatoide negativo (também conhecida como poliartrite, fator reumatoide negativo) também é caracterizada por artrite em cinco ou mais articulações dentro dos primeiros 6 meses da doença. Pessoas com esse tipo, porém, apresentam teste negativo para fator reumatoide no sangue.
A artrite idiopática juvenil psoriásica envolve artrite que geralmente ocorre em combinação com um distúrbio cutâneo chamado psoríase. A psoríase é uma condição caracterizada por manchas de pele vermelha e irritada que frequentemente são cobertas por escamas brancas descamativas. Algumas pessoas afetadas desenvolvem psoríase antes da artrite, enquanto outras desenvolvem artrite primeiro. Outras características da artrite psoriásica incluem anomalias nos dedos e nas unhas ou problemas oculares.
A artrite idiopática juvenil relacionada à entesite é caracterizada por sensibilidade onde o osso se encontra com um tendão, ligamento ou outro tecido conjuntivo. Os locais mais comumente afetados são os quadris, joelhos e pés. Essa sensibilidade, conhecida como entesite, acompanha a inflamação articular da artrite. A artrite relacionada à entesite também pode envolver inflamação em partes do corpo além das articulações.
O último tipo de artrite idiopática juvenil é chamado de artrite indiferenciada. Essa classificação é atribuída a pessoas afetadas que não se enquadram em nenhum dos tipos acima ou que atendem aos critérios para mais de um tipo de artrite idiopática juvenil.
Fonte: MedlinePlus Genetics (NLM/NIH), traduzidoA Artrite Idiopática Juvenil (AIJ) é o nome dado a um grupo de doenças inflamatórias que afetam as articulações, de causa desconhecida, que começam antes dos 16 anos de idade e duram mais de 6 semanas. O termo artrite idiopática juvenil foi escolhido para indicar que não há um mecanismo conhecido que cause a doença e para ressaltar a necessidade de excluir outros tipos de artrite que surgem em condições médicas específicas (em particular, a artrite associada a doenças infecciosas, inflamatórias e hemato-oncológicas).
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 48 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 103 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
11 genes identificados com associação a esta condição.
Persistent Muellerian duct syndrome 1
A form of male pseudohermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males.
Systemic lupus erythematosus
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Juvenile arthritis
A rare, familial form of juvenile arthritis characterized by autosomal recessive inheritance and onset in early childhood of symmetric, chronic joint inflammation. It causes joint swelling, pain, stiffness and restricted joint movement. JUVAR has high clinical variability. Some patients exhibit systemic symptoms, including quotidian fever, erythematous rash, generalized lymphadenopathy, hepatomegaly, and/or splenomegaly. Others display polyarthritis without systemic inflammation.
Rheumatoid arthritis systemic juvenile
An inflammatory articular disorder with systemic onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
Type 1 diabetes mellitus 10
A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Immunodeficiency 25
An immunological deficiency characterized by T-cells impaired immune response to alloantigens, tetanus toxoid and mitogens.
Systemic lupus erythematosus 11
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Immunodeficiency 63 with lymphoproliferation and autoimmunity
An autosomal recessive disorder characterized by immune dysregulation resulting in lymphoid proliferation, dermatitis, enteropathy, autoantibodies, hypergammaglobulinemia, and immunodeficiency with recurrent infections. Patients show increased susceptibility to viral infections, particularly cytomegalovirus disease.
Medicamentos aprovados (FDA)
2 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
92 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 1 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
43 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Artrite juvenil idiopática
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 31 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
22 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
150 ensaios clínicos encontrados, 37 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 5.529
Clinical predictors of relapse and severe disease phenotype in children with non-systemic juvenile idiopathic arthritis.
The aim of this study was to identify the predictors of relapse and severe disease in non-systemic juvenile idiopathic arthritis (JIA), a heterogeneous childhood disease. Patients with JIA were grouped based on relapse status, and those with ≥ 2 relapses requiring biologics were classified as severe disease phenotype. A total of 142 patients (63.4% female) were included in the study. Seventy-three patients (51.4%) experienced at least one relapse after achieving remission, who were significantly characterized by female gender, younger age at diagnosis, positive ANA test, and longer disease duration. Ankle, elbow, metacarpophalangeal (MCP), and temporomandibular joint (TMJ) involvement was more prevalent in patients who had experienced at least one relapse. Longer disease duration, higher number of joints involved at the time of diagnosis, and MCP involvement were found as independent risk factors for relapse. Twenty patients (14%) were grouped as having a severe disease phenotype, characterized by a younger age at the time of diagnosis, longer disease duration, and a higher number of joints involved throughout the disease course. Younger age at diagnosis, ankle involvement, and TMJ involvement were found to be independent risk factors for a severe disease phenotype. In our study, longer disease duration, MCP joint involvement, and a higher number of joints involved at the time of diagnosis were found to be associated with relapse in non-systemic JIA patients. On the other hand, younger age at diagnosis, ankle and TMJ involvement were associated with severe disease phenotype. • JIA is a chronic joint disease characterized by relapses and remissions, and approximately half of patients experience at least one relapse after remission. • Multiple relapses and bDMARD requirement may define a severe disease course. Younger age, ankle, and TMJ involvement may predict severe disease course. • Relapses may occur with longer disease duration; not every relapse implies a severe disease course.
Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous pediatric rheumatic disease characterized by persistent pain, functional limitations, and psychosocial difficulties that frequently persist despite optimized pharmacological treatment. Active Action Observation (AAO), which involves observing and then executing goal-directed movements, has been shown to engage mirror-neuron and visuomotor networks. This approach has shown promise in neurological and orthopedic rehabilitation, but has not been studied in adolescents with JIA. To assess the feasibility, acceptability, and preliminary clinical effects of an eight-week home-based AAO telerehabilitation program in adolescents with JIA. A prospective exploratory case series included 10 adolescents with JIA (11-17 years). The participants completed an eight-week AAO protocol delivered via weekly pre-recorded YouTube videos and brief online follow-up sessions. Outcomes were assessed at baseline, week 4, and week 8 and included pain interference (PROMIS), stress (SSI-SM), self-efficacy (GSES), fear of pain (FOPQ-III), Timed Up and Go (TUG), hand-grip strength, 6-min walk test (6MWT), and cervical pressure pain thresholds (PPT). The analyses focused on descriptive statistics, change scores, percentage change, and robust estimators (Hodges-Lehmann, Kendall's W). AAO was feasible and well accepted, with no participants withdrawing, and only mild and transient adverse effects reported. From baseline to week 8, the median changes were -42.1% for pain interference, -22.2% for stress, +18.8% for self-efficacy, and -25.7% for fear of pain/movement. While functional mobility (TUG) showed improvement, handgrip strength and 6-min walk test responses were found to be heterogeneous, and cervical PPT exhibited a pattern of increased sensitivity. In line with AAO's neurocognitive framework, the observed reduction in fear of pain, coupled with increased self-efficacy and reduced stress, may indicate an update in threat-related motor representations. This update disrupts the previously formed "movement = danger" association, thereby enabling safer functional engagement and less pain interference. AAO delivered at home via telerehabilitation appears to be a feasible, acceptable, and potentially beneficial adjunct for adolescents with JIA, particularly for pain-related and psychological outcomes. These preliminary findings support the feasibility of AAO and justify future controlled trials to establish its efficacy and elucidate the underlying mechanisms.
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
Juvenile psoriatic arthritis and enthesitis-related arthritis are two categories of juvenile idiopathic arthritis (JIA). Despite available treatments including non-steroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, a substantial proportion of people do not adequately respond to treatment or do not have long-lasting clinical remission. The aim of this trial was to show the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis. COSPIRIT-JIA is an ongoing multicentre, open-label, phase 3 study of ixekizumab, with a randomised adalimumab reference group, in children with a diagnosis of enthesitis-related arthritis (aged 6 to <18 years) and juvenile psoriatic arthritis (aged 2 to <18 years). Eligible participants had three or more active peripheral joints (presence of swelling or limited motion with pain or tenderness) and a bodyweight of at least 10 kg. Participants received subcutaneous administration of either ixekizumab or adalimumab using a weight-based dosing regimen (ixekizumab 40-160 mg starting dose then 20-80 mg once every 4 weeks; and adalimumab 20-40 mg once every 2 weeks). The primary endpoint was the percentage of ixekizumab-treated participants meeting the JIA-American College of Rheumatology (ACR) 30 (defined as at least 30% improvement from baseline in three of any six core outcome variables, with no more than one of the other variables worsening by more than 30%) response criteria at week 16. A Bayesian analysis was used to assess JIA-ACR30 response rate at week 16. Safety data were summarised using descriptive statistics for all participants who received at least one dose of either treatment. People with lived experience of JIA were not involved in the design or conduct of this study. The trial was registered with ClinicalTrials.gov, NCT04527380. The study enrolled 101 patients (ixekizumab n=81, adalimumab n=20) between April 13, 2021, and April 2, 2024, of whom the initial 40 participants naive to biological DMARD treatment were randomly assigned 1:1 to ixekizumab or adalimumab and the additional 61 participants were assigned to ixekizumab. Of the 81 participants who received ixekizumab, 60 were biological DMARD naive (40 with enthesitis-related arthritis and 20 with juvenile psoriatic arthritis) and 21 were biological DMARD experienced (14 with enthesitis-related arthritis and seven with juvenile psoriatic arthritis). The median age of the participants in the ixekizumab group was 14 years (12·0-15·0), of whom 36 (44%) of 81 were female, and 69 (85%) of 81 were White. At week 16, 90% (54 of 60; 95% CI 82·4-97·6) of biological DMARD-naive participants and 86% (18 of 21; 70·7-100·0) of biological DMARD-experienced participants receiving ixekizumab had a JIA-ACR30 response. Treatment-emergent adverse events were mostly mild (46%) or moderate (36%) for the ixekizumab group, with no severe treatment-emergent adverse events reported. The safety profile was consistent with adult psoriatic arthritis or spondyloarthritis and paediatric psoriasis indications. Ixekizumab was well tolerated and effective for the treatment of children with enthesitis-related arthritis and juvenile psoriatic arthritis who are candidates for biological DMARD therapy. Eli Lilly and Company.
Metabolic masqueraders of paediatric and adult rheumatic diseases.
Inborn errors of metabolism comprise a clinically diverse group of conditions that arise from the decreased activity of an enzyme or metabolite transporter and subsequent blockade in a metabolic pathway. These disorders are typically considered in the differential diagnosis of critically ill neonates or young children presenting with hypoglycaemia, metabolic acidosis or hyperammonaemia. However, beyond these classic presentations, a broader group of inborn errors of metabolism can manifest more subtly, with progressive articular and multi-systemic involvement that mimics or overlaps with typical features of rheumatological disease. Consequently, these conditions might be misdiagnosed for years as rheumatological diseases, including juvenile idiopathic arthritis, systemic sclerosis, idiopathic inflammatory myopathies and systemic lupus erythematosus. Moreover, these disorders provide unique opportunities to understand the complex interplay between metabolism and immune function. With the growing availability of disease-modifying therapies for inborn errors of metabolism, rheumatologists must be able to recognize these disorders, particularly in patients with atypical features or treatment-refractory disease.
Prioritising conditions resulting in chronic lower limb musculoskeletal pain in children and adolescents for development of clinical practice guidelines: an Australian Delphi study.
Children and adolescents with chronic lower limb pain may experience delayed diagnosis, misdiagnosis, insufficient or inappropriate treatment initiation or type. Developing condition-specific clinical practice guidelines is one approach to address these healthcare challenges. This research aimed to prioritise the top 10 conditions resulting in chronic lower limb musculoskeletal pain in children that would benefit from the development of Australian clinical practice guidelines. We conducted a modified three round eDelphi. Three multidisciplinary panels were provided a summary of current available evidence and any clinical practice guidelines currently available for 124 conditions identified as resulting in chronic lower limb pain. Panels rated their agreement on the need for the development of clinical practice guidelines and ranked the top 10 conditions. In the final round, parents of children with chronic lower limb musculoskeletal pain rated the appropriateness of the top 10 conditions for guideline development. Forty-four Australian health care professionals (22 allied health, 7 paediatric medical specialists, and 13 general practitioners) participated in Rounds 1 and 2 with a retention rate of 100%. Sixteen parents participated in the confirmatory round. The top 10 conditions prioritised for clinical practice guideline development were generalised joint hypermobility, growing pains, musculoskeletal pain, Juvenile Idiopathic Arthritis, joint instability, avascular necrosis, Legg-Calve-Perthes, flat foot, slipped capital femoral epiphysis and patellofemoral pain syndrome. Healthcare professionals prioritised 10 conditions that require development of clinical practice guidelines. Parents of children and adolescents with chronic lower limb pain provided feedback on the appropriateness of the 10 prioritised conditions for guideline development. These guidelines should be multidisciplinary, co-designed with families and relevant to all health settings. The online version contains supplementary material available at 10.1186/s12887-026-06600-4.
Publicações recentes
Validation of a semi-quantitative ultrasonography score for knee synovitis in juvenile idiopathic arthritis and its association with clinical findings.
Investigating the utility of sarcopenia associated SARC-F and MSRA questionnaires in identifying falls and self-reported functional impairment in juvenile idiopathic arthritis.
The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Juvenile Idiopathic Arthritis (JIA): Polyarticular Course JIA, Temporomandibular Joint Arthritis, Imaging, and Non-Pharmacologic Therapies.
[Clinical characteristics and outcomes analysis of children with rheumatoid factor-positive polyarticular juvenile idiopathic arthritis].
Turner syndrome as a state of increased autoimmune susceptibility: evidence from rheumatic diseases.
📚 EuropePMC6.221 artigos no totalmostrando 197
Distinguishing acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with musculoskeletal complaints: a retrospective cross-sectional study.
BMC pediatricsModeling, Simulation, and Extrapolation to Optimize Pediatric Development Plan: Sarilumab Polyarticular-Course juvenile arthritis Application.
Journal of pharmacokinetics and pharmacodynamicsPerformance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis.
Drug delivery[Noninfectious uveitis in childhood : Clinical aspects, diagnostics, treatment and transition].
Die OphthalmologieMethotrexate Therapy in Juvenile Idiopathic Arthritis: No Clinically Relevant Pulmonary Impairment but Frequent Transient Liver Enzyme Elevations in a Longitudinal Single-Center Pediatric Cohort of 274 Children Over 30 Years.
ACR open rheumatologyThe gut-joint axis in juvenile idiopathic arthritis.
Arthritis research & therapyClinical predictors of relapse and severe disease phenotype in children with non-systemic juvenile idiopathic arthritis.
European journal of pediatricsApplication of a novel Musculoskeletal Ultrasound Sum Score (MUSS) in the follow-up of patients with juvenile idiopathic arthritis.
Rheumatology (Oxford, England)A proposal for the implementation of telemedicine in Japan for rheumatoid arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus: review article.
Modern rheumatologyMorel Lavallée Lesion Following Excessive Physiotherapy for Ankle Arthritis in a Child with Juvenile Idiopathic Arthritis: Correspondence.
Indian journal of pediatricsClinical characteristics and quality of life measures in children with glaucoma-suspect or glaucoma diagnoses in chronic, noninfectious uveitis.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and StrabismusEtiologies of Wrist Arthritis in the Young Patient.
Hand clinicsAA amyloidosis in inflammatory joint diseases in the era of biological therapies: prevalence, manifestations, management and evolution.
Joint bone spineThe Auditory Manifestations of Autoimmune Rheumatologic Diseases: A Review of Current Evidence.
Current rheumatology reviewsRheumatic diseases in childhood: Clinical and immunological characteristics of a pediatric cohort at a tertiary hospital.
Reumatologia clinicaSingle-centre observational study of anti-adalimumab antibody development in children and young people treated for juvenile idiopathic arthritis and/or non-infectious uveitis.
The British journal of ophthalmologyA Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient.
Rheumatology and therapyParadoxical Expression of Ionotropic Glutamate Receptors in Leucocytes.
Clinical reviews in allergy & immunologyEffects of very early arthritis on pain, behavior, and hippocampal TNF/BDNF in rats.
Pediatric researchLong-term comorbidity patterns in juvenile idiopathic arthritis.
Clinical and experimental rheumatologyOverview of elbow arthritis, a rare involvement in patients with juvenile idiopathic arthritis.
Advances in rheumatology (London, England)Pregnancy outcomes in juvenile idiopathic arthritis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center)Juvenile idiopathic arthritis and pregnancy.
Proceedings (Baylor University. Medical Center)Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.
Frontiers in human neuroscienceCost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand.
Value in health regional issuesClinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.
Clinical rheumatologyReal-world use of biologics for non-systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database.
Modern rheumatologyHighlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.
Mediterranean journal of hematology and infectious diseasesBrachial artery flow-mediated dilation is less repeatable in children with a chronic inflammatory disease compared to their healthy peers.
Clinical physiology and functional imagingHematopoietic Stem Cell Transplantation in Rheumatic Diseases.
International journal of rheumatic diseasesDefining Inactivity of Juvenile Spondyloarthropathies: Delphi Study Among Pediatric Rheumatology Academy (PeRA) From Türkiye.
International journal of rheumatic diseasesAssociation between asthma and juvenile idiopathic arthritis in children in the United States: a propensity score weighted cross-sectional study.
Pediatric rheumatology online journalEfficacy of combined JAK1/2 inhibition and cyclosporine in paediatric-onset Still's disease with lung involvement: a case report.
Pediatric rheumatology online journalACR Appropriateness Criteria® Joint Pain: Idiopathic Arthritis-Child.
Journal of the American College of Radiology : JACREfficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study.
Rheumatology and therapy2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.
RMD openHigh Healthcare Utilization Preceding Diagnosis with Juvenile Idiopathic Arthritis.
Arthritis care & researchTrajectories of Physical Function in Canadian Children with Juvenile Idiopathic Arthritis.
Arthritis care & researchReliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease.
ACR open rheumatologySoluble factors released from fibroblast-like synoviocytes of JIA patients with future extended course can condition persistent JIA synovial fibroblasts for increased IL-6 production.
Arthritis research & therapyIncidence and Prevalence of Non-Infectious Uveitis: A Systematic Review and Meta-Analysis.
Retina (Philadelphia, Pa.)Disease Damage in Juvenile Idiopathic Arthritis: Authors' Reply.
Indian journal of pediatricsIxekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
The Lancet. RheumatologyTargeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.
InflammopharmacologyAn abnormal immune response masquerading as infectious conditions.
SAGE open medical case reportsCamptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.
Klinische PadiatriePrevalence and risk factors for acute kidney injury at the diagnosis of juvenile idiopathic arthritis in children and its long-term implications for kidney health.
Pediatric nephrology (Berlin, Germany)Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents.
Expert opinion on drug safetySynovial fluid potentiates local fibroblasts to drive monocyte activation in juvenile idiopathic arthritis.
Arthritis research & therapyNovel advances in juvenile idiopathic arthritis associated uveitis.
Arthritis research & therapyCharacterization of JIA subtypes, clinical features, treatment patterns, and early outcomes in Palestinian children: a retrospective cohort study.
Pediatric rheumatology online journal[Imaging in hip disorders in childhood and adolescence].
Orthopadie (Heidelberg, Germany)Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.
Pharmaceuticals (Basel, Switzerland)The Effects of Microbiome Modulating Therapies on Inflammatory Markers in Autoimmune Disease: A Systematic Review and Meta-Analysis.
NutrientsMetabolic and Anthropometric Alterations in Juvenile Idiopathic Arthritis: A Focus on Cardiometabolic Risk and Non-Invasive Evaluation Methods.
MetabolitesMetabolic masqueraders of paediatric and adult rheumatic diseases.
Nature reviews. RheumatologyChallenges in functional validation and mechanistic interpretation of a novel LACC1 variant in familial juvenile arthritis.
Human genomicsThe impact of time to diagnosis on health service use, cost, and quality of life for patients with juvenile idiopathic arthritis: a cost-utility analysis.
Pediatric rheumatology online journalInosine-Triphosphate-Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis.
Arthritis & rheumatology (Hoboken, N.J.)Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method.
CytokinePrioritising conditions resulting in chronic lower limb musculoskeletal pain in children and adolescents for development of clinical practice guidelines: an Australian Delphi study.
BMC pediatricsA multifaceted interplay between hemophagocytosis, IL-18 and type I IFN distinguishes Still disease from other autoinflammatory diseases.
Arthritis & rheumatology (Hoboken, N.J.)Pan American League of Associations for Rheumatology: Recommendations for the Treatment of Oligoarticular Juvenile Idiopathic Arthritis.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesCase Report: A case of autoinflammatory disease with a novel NLRP12 variant-clinical presentation and successful treatment with baricitinib.
Frontiers in medicineDrug-induced liver injury secondary to anakinra in a patient with systemic juvenile idiopathic arthritis-Case report and literature overview.
Canadian liver journalBiologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.
Expert opinion on biological therapyDevelopment and validation of a multi-institutional electronic juvenile idiopathic arthritis phenotype.
Seminars in arthritis and rheumatismDisease Damage in Juvenile Idiopathic Arthritis: Correspondence.
Indian journal of pediatricsAdherence to Disease Modifying Anti Rheumatic Drugs in Tunisian patients with Juvenile Idiopathic Arthritis: An Observational study.
La Tunisie medicaleDiscordance between non-zero physician's global scores and absence of active joints in juvenile idiopathic arthritis: multicenter vs. single-center cohorts.
Frontiers in pediatricsSymptoms and correlates of depression and anxiety in children and adolescents with juvenile idiopathic arthritis.
Orphanet journal of rare diseasesInterferon-Driven Tryptophan Metabolism Links Inflammation and Mental Health in Juvenile Dermatomyositis.
InflammationMechanobiologic modulation of TMJ loading in juvenile idiopathic arthritis.
Cranio : the journal of craniomandibular practiceMoving towards optimized treatment for children and adolescents with juvenile idiopathic arthritis in sustained remission randomized to continue stable treatment, methotrexate withdrawal or tumor necrosis factor inhibitor withdrawal: study protocol for the Norwegian multi-center MOVE-JIA trial.
TrialsClinical characteristics of temporomandibular joint involvement in children with juvenile idiopathic arthritis.
European archives of paediatric dentistry : official journal of the European Academy of Paediatric DentistryAn etiopathogenesis of juvenile idiopathic arthritis: the protein-homeostasis-system hypothesis.
Frontiers in pediatricsOsteopathia striata with cranial sclerosis, associated with juvenile idiopathic arthritis: A case report and review of literature.
World journal of orthopedicsRapidly progressive fibrinopurulent pleural empyema with systemic juvenile idiopathic arthritis during treatment with tocilizumab.
Rheumatology advances in practiceAutoantibody signatures in children with celiac disease, juvenile idiopathic arthritis, and polyautoimmunity.
JPGN reportsMorel Lavallée Lesion Following Excessive Physiotherapy for Ankle Arthritis in a Child with Juvenile Idiopathic Arthritis.
Indian journal of pediatricsTemporomandibular joint manifestation of autoimmune diseases.
The Saudi dental journalCombination of Methotrexate and Mycophenolate mofetil for Refractory Uveitis & Scleritis: A Case Series.
Retinal cases & brief reportsWhole-body magnetic resonance imaging in rheumatology: advancements, key applications and future perspectives.
La Radiologia medicaModel-Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease.
Journal of clinical pharmacologyHip Joint Synovial Cavity Thickness in Early Juvenile Idiopathic Arthritis Without Effusion: A Cross-Sectional Ultrasound Study.
Journal of clinical medicineFrom Juvenile Idiopathic Arthritis to Pachydermoperiostosis: A Journey to an Unexpected Rare Diagnosis.
Journal of clinical medicineSerum bile salt-stimulated lipase levels associates with systemic inflammation and declines with effect of treatment in juvenile idiopathic arthritis.
Pediatric rheumatology online journalImaging TMJ in juvenile idiopathic arthritis: beyond accuracy toward clinical impact.
Oral surgery, oral medicine, oral pathology and oral radiologyImpact of the 2018 Japan Floods on Methotrexate and Antirheumatic Drug Prescriptions: A Longitudinal Analysis of the Japanese National Database.
JMA journalDecoding pulmonary risk in childhood-onset still's disease: immunogenetic determinants and implications for risk stratification.
Respiratory researchSuperb microvascular imaging ultrasound of the knee in patients with juvenile idiopathic arthritis-a repeatability study.
Frontiers in pediatricsTreatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First-Line Therapy.
Arthritis & rheumatology (Hoboken, N.J.)Atypical Early Presentation of Multicentric Carpotarsal Osteolysis: Ankle Pain and Cavovarus Deformity Without Osteolysis.
CureusInflammatory ankle MRI findings in pediatric and young adult patients with familial Mediterranean fever: a comparison with juvenile idiopathic arthritis and chronic nonbacterial osteomyelitis.
Skeletal radiologyClinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseases.
The Journal of allergy and clinical immunologyChanging paediatric uveitis patterns in Italy: an eight-year experience from the Reggio Emilia Uveitis clinic.
International ophthalmologyAltered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis.
Nature communicationsCausal relationship between body mass index and risk of juvenile idiopathic arthritis: A 2-sample Mendelian randomization study.
MedicineJuvenile Idiopathic Arthritis Registry at King Abdullah Specialized Children's Hospital (JIAR-KASCH) in Riyadh, Saudi Arabia.
Saudi medical journalStill's Disease and Autoinflammation: Positioning an Inflammatory Syndrome on the Autoinflammation-Autoimmunity Spectrum.
Current rheumatology reportsFrom Misdiagnosis to Genetic Confirmation: A Brazilian Familial Report of Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome-A Case-Based Review.
Case reports in pediatricsDeep learning and radiomics-based system for early diagnosis of hip synovitis in juvenile idiopathic arthritis.
Frontiers in immunologyPRO-KIND consensus protocol for classification, monitoring, and therapy in pediatric rheumatology: persistent oligoarticular juvenile idiopathic arthritis.
Frontiers in pediatricsNon-systemic Juvenile Idiopathic Arthritis: How do the provisional PRINTO criteria shape the classification?
The Journal of rheumatologyUnderstanding the Current Landscape of Health Disparities Research Among Youth With Juvenile Idiopathic Arthritis.
The Journal of rheumatologyA 15-Year-Old Patient With History of Juvenile Idiopathic Arthritis Presenting With a Painful Skin Rash.
Pediatrics in reviewReassessing the prevalence of monophasic, polyphasic and persistent disease courses in still's disease.
Seminars in arthritis and rheumatismSafety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study.
Rheumatology and therapyDietary and complementary oral supplements for the management of chronic diseases in children: a systematic review.
Frontiers in pediatricsGlobal burden and genetic insights of RA and JIA in ages 0-19 years: GBD 2021 and MR analysis.
Frontiers in immunologyCharacterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review.
Pediatric dermatologyComparative risk of systemic autoimmune diseases in juvenile idiopathic arthritis treated with TNF-α or IL-6 inhibitors: a real-world cohort study.
Frontiers in immunologyAdvancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.
Mediterranean journal of rheumatologyToward Personalized Withdrawal of TNF-α Inhibitors in Non-Systemic Juvenile Idiopathic Arthritis: Predictors of Biologic-Free Remission and Flare.
Pharmaceuticals (Basel, Switzerland)Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.
Pharmaceuticals (Basel, Switzerland)Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.
Journal of clinical medicineEarly-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases.
MicroorganismsGait Characteristics in Children with Juvenile Idiopathic Arthritis and Secondary Scoliosis.
Children (Basel, Switzerland)The Impact of Vitreoretinal Surgery in Patients with Uveitis: Current Strategies and Emerging Perspectives.
Diagnostics (Basel, Switzerland)Physical activity in children aged 7-13 years with juvenile idiopathic arthritis. Is it significantly altered? A case-control study.
ReumatologiaFrom arthritis to central sensitization: targeting the neuro-immune axis via microglial modulation in acupuncture treatment for Juvenile Idiopathic Arthritis-associated pain.
Frontiers in immunologyMuscle mass, strength, and sarcopenia in juvenile idiopathic arthritis: a scoping review.
Pediatric rheumatology online journalTeMPRA: advancing continuing professional development in pediatric rheumatology in Japan.
Pediatric rheumatology online journalTemporomandibular disorder in children with juvenile idiopathic arthritis with and without temporomandibular joint involvement compared to controls - a two-year prospective multicenter cohort study.
BMC oral healthIdentification of potential diagnostic biomarkers for systemic juvenile idiopathic arthritis by integrative transcriptomic analysis.
AutoimmunityJuvenile rhupus syndrome: A case report of coexistence of JIA and SLE.
MedicineEvaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study.
Pediatric rheumatology online journalEffectiveness of Biological Treatment on Hip Involvement in Inflammatory Rheumatic Diseases.
Current rheumatology reviewsUltrasound to Assess the Temporomandibular Joint of Children With Juvenile Idiopathic Arthritis: A Systematic Review.
International journal of dentistryToward Optimal Treatment Outcomes in New-Onset Polyarticular-Course Juvenile Idiopathic Arthritis.
Paediatric drugsThe association between Children's sleep quality and juvenile idiopathic arthritis.
Frontiers in pediatricsRenal involvement in different subtypes of children with juvenile idiopathic arthritis: results from a single-center cohort.
Clinical rheumatologyEffect of exercise interventions on physical function, cardiorespiratory fitness, and health-related quality of life in patients with juvenile idiopathic arthritis: a meta-analysis of randomized controlled trials.
BMC pediatricsMental health needs of children and young people with arthritis.
Arthritis research & therapyAortic Valve Regurgitation in a Girl With Juvenile Idiopathic Arthritis.
JACC. Case reportsA retrospective study of pediatric rheumatology referrals reveals large discrepancies in referring providers' musculoskeletal exams.
Pediatric rheumatology online journalNMR-based metabolomics reveals distinct metabolic profiles in juvenile systemic lupus erythematosus and juvenile idiopathic arthritis.
Clinica chimica acta; international journal of clinical chemistrySerum Calprotectin - What is the Scope of Clinical Application?
Clinical laboratorySex Differences in PROMIS Pediatric Depressive Symptoms, Anxiety, and Psychological Stress Among Children and Adolescents Living With Pediatric Rheumatic Diseases.
The Journal of rheumatologyTrials augmented by external control data using balancing weights: A comparison of estimands and estimators.
Contemporary clinical trialsUse of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry.
Clinical rheumatologyTen-Year Registry Analysis of Ocular Inflammation in Taiwan: Distinct Clinical Patterns and Systemic Associations in Adults and Children.
Ocular immunology and inflammationExploring the Association Between Autoimmune and Inflammatory Diseases and Uveitis.
American journal of ophthalmologyTocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report.
SAGE open medical case reportsEvaluating the osteoclastogenic potential of peripheral blood mononuclear cells in children with chronic nonbacterial osteomyelitis.
JBMR plusSystemic Onset Juvenile Idiopathic Arthritis in Sickle Cell Anaemia: A Diagnostic Odyssey.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionImpaired Generation of High-Affinity Memory B Cells and Neutralizing Antibodies Against SARS-CoV-2 in Adolescents and Young Adults With Juvenile Idiopathic Arthritis Treated With Tumor Necrosis Factor Inhibitors.
ACR open rheumatologyTransformation of juvenile idiopathic arthritis in adult-oriented rheumatology care.
Turkish journal of medical sciencesDry synovitis, RF-negative: a rare entity distinct from juvenile idiopathic arthritis.
Rheumatology advances in practiceDevelopment of a scoring system to assist clinicians in the early referral of patients with suspected juvenile idiopathic arthritis: the EasyJIA score.
Arthritis research & therapyThe ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis.
Eye (London, England)Parent and Physician Global Assessment Discordance in Juvenile Arthritis: The Role of Pain Coping Strategies.
Journal of pediatrics. Clinical practiceMapping the Global Landscape of Temporomandibular Disorders Research in Children and Adolescents From 2000 to 2024: A Bibliometric Analysis.
Pain research & managementPAFLAR guidelines for oligoarticular juvenile idiopathic arthritis.
Clinical rheumatologyNovel hematological indices SII and NLR: Aiding diagnosis, differentiating subtypes, and reflecting disease activity in juvenile idiopathic arthritis.
Journal of orthopaedicsPrevalence and clinical risk factors for methotrexate intolerance in patients with juvenile idiopathic arthritis.
ARP rheumatologyRescue Therapy With Continuous Intravenous Anakinra Infusion and Plasma Exchange in Refractory Cytokine Storm of Systemic JIA: A Case Report.
Case reports in pediatricsThe epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up.
Frontiers in immunologyGive weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology.
Arthritis research & therapySustained hippocampal neuroinflammation and subsequent glutamatergic dysfunction in juvenile idiopathic arthritis: evidence from proton magnetic resonance spectroscopy (1H-MRS).
Arthritis research & therapyAdoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.
Pediatric rheumatology online journalCirculating Aggrecan, Biglycan, and Decorin as Biomarkers of Osteoarticular Alterations in Juvenile Idiopathic Arthritis-A Preliminary Study.
International journal of molecular sciencesA Canadian Advanced Physiotherapist Practitioner Shared-Care Model in Pediatric Rheumatology Offers Safe and Quality Care in the Management of Juvenile Idiopathic Arthritis-Comparing Key Performance Indicators with the PR-COIN Registry.
Children (Basel, Switzerland)Regional Gastrointestinal Permeability Patterns in Juvenile Idiopathic Arthritis: A Window into Subclinical Inflammation and Microbiota-Driven Disease Mechanisms.
Children (Basel, Switzerland)[Predicting and in vitro validating new indications of Ginkgolide B via network-medicine framework].
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesCommentary on "Effects of Hydrotherapy on Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis".
Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy AssociationPharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).
Rheumatology and therapyClosed Loop Computer-based Artificial Intelligence Model "Maverik" to Help Diagnose and Differential Diagnoses of Childhood Onset Chronic Nonbacterial Osteomyelitis: Pilot Study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesFunctional and Computational Interrogation of the Juvenile Idiopathic Arthritis Risk Loci Identifies Candidate Causal SNPs and Target Genes in CD4+ T cells.
medRxiv : the preprint server for health sciencesPharmacogenetic hSLCO1B1*14-Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response.
Clinical and translational scienceNot Just Sjögren's: A Rare Life-Threatening Manifestation in a Pediatric Patient.
CureusGlobal research trends in MRI of temporomandibular disorders: a bibliometric study and visualization analysis via CiteSpace.
Journal of oral & facial pain and headacheDiagnostic impact of tocilizumab on papillary thyroid cancer in a patient with systemic juvenile idiopathic arthritis.
Rheumatology (Oxford, England)Anti-phospholipase A2 Receptor-associated Membranous Nephropathy in an Adolescent Boy with HLA-B27-positive Juvenile Idiopathic Arthritis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi ArabiaNonsteroidal Anti-Inflammatory Drug-Induced Granulomatous Interstitial Nephritis in Juvenile Idiopathic Arthritis: A Rare Entity.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi ArabiaA comprehensive report of disease complications of juvenile idiopathic arthritis using a prospective cohort study.
Pediatric rheumatology online journalClinical predictive factors for septic arthritis of the knee in children: A cohort study.
Science progressThe role of systemic immune-inflammation index in differentiation of juvenile idiopathic arthritis from reactive arthritis among Chinese children.
Frontiers in medicineRisk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis.
Frontiers in pediatricsRisk of uveitis among children with autoimmune diseases: a nationwide matched-cohort study of 3,643 cases.
Frontiers in immunologyNovel insights into the biology of childhood arthritis- lessons learned from the synovium.
Arthritis research & therapyComparing Orofacial Manifestations and Oral Health-Related Quality of Life in Previously Treated Young Adults With Idiopathic Condylar Resorption or Juvenile Arthritis in the Temporomandibular Joint.
Orthodontics & craniofacial researchHip chondrolysis due to enthesitis-related juvenile idiopathic arthritis treated successfully with adalimumab: A case report.
Modern rheumatology case reportsP19 A rare case of PHOAR2-enteropathy syndrome (PHOAR2E; previously known as pachydermoperiostosis) with a causal variant in the SLCO2A1 gene.
The British journal of dermatologyGut dysbiosis and inflammation in patients with Juvenile Idiopathic Arthritis-Enthesitis Related Arthritis: impact of HLA-B27 status.
Clinical rheumatologyCompositional patterns of device-measured movement behaviour in juvenile idiopathic arthritis: results from the multicentre ActiMON study.
Arthritis research & therapyAge-Related Osseous Measures of the Temporomandibular Joint and Mandibular Ramus During Childhood Assessed by Magnetic Resonance Imaging.
Orthodontics & craniofacial researchMulticentric carpo-tarsal osteolysis: the importance of imaging studies, genetic findings and clinical expertise in differential diagnosis and follow-up-a case report.
Skeletal radiologyDisseminated Histoplasmosis Following a Single Dose of Adalimumab in a Child With Juvenile Idiopathic Arthritis: Case Report.
The Pediatric infectious disease journalChanges in Modern Care for Juvenile Idiopathic Arthritis: How Much Does This Affect Health-Related Quality of Life?
The Journal of rheumatologyExamination of HLA-DRB1*15-linked Candidate Antigens in Still Disease With and Without Lung Disease and Drug-Associated Immune Reactions.
The Journal of rheumatologyHepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.
The Journal of rheumatologyCausal effect of type 1 diabetes on juvenile idiopathic arthritis and the mediating role of CD8+ natural killer T cells.
The Journal of clinical endocrinology and metabolismPediatric rheumatic diseases and vaccinations: a promising alliance.
Frontiers in pediatricsMethotrexate use in juvenile idiopathic arthritis and its impact on growth plate development: A prospective observational cohort study.
BioinformationBaseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort.
Arthritis care & research[Juvenile idiopathic arthritis-persistent oligoarticular subtype : Consensus-based treatment recommendations as part of the ProKind Rheuma Initiative].
Zeitschrift fur RheumatologieAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Artrite juvenil idiopática.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Artrite juvenil idiopática e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É um grupo de doenças inflamatórias nas articulações que surge antes dos 16 anos e persiste por mais de seis semanas. Trata-se de uma desordem autoimune que ataca tecidos e articulações da própria criança ou adolescente.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 9 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Artrite juvenil idiopática. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/artrite-juvenil-idiopatica
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Artrite juvenil idiopática
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Ensaios clínicos
- fonte: ClinicalTrials.gov
